Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (Rovatitan
effectiveness
hyperlipidemia
hypertension
rosuvastatin
safety
valsartan
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
10
2022
accepted:
23
02
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
This study aimed to assess the effectiveness and safety of a fixed-dose combination of rosuvastatin and valsartan (Rovatitan A total of 1008 eligible patients with concomitant hypertension and hyperlipidemia were enrolled and treated for 12 weeks. Both upward and downward drug dose titrations were allowed based on the investigator's discretion. This study evaluated the effectiveness of the study drug, defined by the percentage of patients achieving the blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) treatment targets. Additionally, regression analyses were conducted to evaluate the factors associated with the effectiveness and safety of the study drug. Of the 1008 patients enrolled in the study, 911 were analyzed for clinical effectiveness. At 12 weeks, 84.6% and 75.9% of patients treated with the study drug achieved their BP and LDL-C targets, respectively, and 64.8% of patients achieved both targets simultaneously. Furthermore, the percentage of patients who achieved their BP and LDL-C treatment targets demonstrated a trend across the respective risk groups; the higher the risk group, the lower the success of attaining the respective target. This trend was also observed regardless of the prior antihypertensive and/or lipid-lowering treatments. According to regression analysis, poor metabolic profiles, including a higher body mass index (BMI) and higher BP and LDL-C levels at baseline, were significantly associated with treatment failure for BP. Among the 1005 patients included in the safety analysis, 17 patients (1.7%) experienced serious adverse events; however, none were considered related to the study drug. The study drug used for the treatment of concomitant hypertension and hyperlipidemia in a real-world setting was effective and was well tolerated. Therefore, the study drug is suggested as a good alternative to increase patient convenience and compliance, particularly in those taking multiple medications.
Identifiants
pubmed: 37051292
doi: 10.2147/DDDT.S391288
pii: 391288
pmc: PMC10084874
doi:
Substances chimiques
Rosuvastatin Calcium
83MVU38M7Q
Valsartan
80M03YXJ7I
Cholesterol, LDL
0
Antihypertensive Agents
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1047-1062Informations de copyright
© 2023 Lee et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
Am J Manag Care. 2004 Dec;10(12):926-32
pubmed: 15617368
Lancet. 2007 Jan 20;369(9557):201-7
pubmed: 17240286
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
Curr Opin Nephrol Hypertens. 2002 Sep;11(5):489-96
pubmed: 12187312
Diabetes Care. 2011 Jun;34(6):1323-8
pubmed: 21505206
Clin Ther. 2018 May;40(5):676-691.e1
pubmed: 29673890
Clin Ther. 2019 Aug;41(8):1508-1521
pubmed: 31307833
Drug Des Devel Ther. 2016 Aug 16;10:2599-609
pubmed: 27574399
Atherosclerosis. 2007 Sep;194(1):1-45
pubmed: 17880983
Ann Intern Med. 1971 Jan;74(1):1-12
pubmed: 5539274
J Hypertens. 2013 Jul;31(7):1281-357
pubmed: 23817082
Clin Ther. 2016 Oct;38(10):2171-2184
pubmed: 27742464
J Hypertens. 2007 Jun;25(6):1105-87
pubmed: 17563527
Adv Ther. 2019 Jun;36(6):1426-1437
pubmed: 30953331
Int J Clin Pract Suppl. 2004 Oct;(143):30-40
pubmed: 16035394
Drug Des Devel Ther. 2019 Feb 13;13:633-645
pubmed: 30858694
Circulation. 2005 May 17;111(19):2518-24
pubmed: 15867169
Eur J Prev Cardiol. 2016 Apr;23(6):636-48
pubmed: 25687109
Heart. 2017 Sep;103(17):1339-1346
pubmed: 28285267
Hypertension. 2003 Dec;42(6):1206-52
pubmed: 14656957
J Clin Hypertens (Greenwich). 2011 Sep;13(9):677-86
pubmed: 21896150
Am J Med. 1986 Feb 14;80(2A):23-32
pubmed: 3946458
Circ J. 2021 Apr 23;85(5):595-603
pubmed: 33790135
Endocrinol Metab (Seoul). 2017 Mar;32(1):36-40
pubmed: 28116871
Am J Med. 2007 Aug;120(8):713-9
pubmed: 17679131
J Hypertens. 2013 Aug;31(8):1702-13
pubmed: 23743804
Circ Res. 2017 Jan 6;120(1):229-243
pubmed: 28057795
Hypertens Res. 2017 Dec;40(12):947-963
pubmed: 28978986
Clin Ther. 2008 Jun;30(6):1145-54
pubmed: 18640470
Korean Circ J. 2015 May;45(3):225-33
pubmed: 26023311
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Mayo Clin Proc. 2008 Jan;83(1):35-45
pubmed: 18174006
J Clin Hypertens (Greenwich). 2005 May;7(5):264-73
pubmed: 15886529
Am J Med. 1986 Feb 14;80(2A):33-9
pubmed: 3946459
Postgrad Med. 2014 Jan;126(1):66-77
pubmed: 24393753
Hypertension. 2015 Mar;65(3):517-24
pubmed: 25601929